CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 391 enrolled
Drug / intervention
Avandamet +2 moredrug
Likely dose
Avandamet 2/500 mg twice daily titrated up to 4/1000 mg twice daily; or Avandia 4 mg once daily + Amaryl 1 mg once daily; or Metformin 500 mg twice daily up to 1000 mg dailyAI-extracted
Key inclusion· 5
  • Type 2 diabetes, drug naïve or on submaximal oral monotherapy for <3 years
  • Age 18-75 years
  • A1C 7.1-10% if drug naïve (after diet/lifestyle failure)
  • A1C 7.1-9% if on single therapy (≤10 mg glyburide, ≤4 mg Amaryl, or ≤1000 mg metformin)
Key exclusion· 12
  • Type 1 diabetes
  • Current insulin treatment
  • Prior thiazolidinedione (TZD) use within 3 months
  • Uncontrolled clinically significant concomitant illness that may limit study participation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00131664
NCT00131664Phase 3Completed

Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients

Canadian Heart Research Centre·interventional·Posted Aug 19, 2005·Updated Apr 17, 2013

In Brief

A Phase 3 clinical trial evaluating Avandamet, Avandia and Amaryl, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 391 participants across 1 site.

Detailed Summary

The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The guidelines on the use of antihyperglycemic agents identify the potential benefits of sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral antihyperglycemic monotherapy who then start on combination therapy may not achieve the required target glycemic control. Indeed early initiation of combination therapies may be necessary to achieve and maintain glycemic targets because of the progressive deterioration of pancreatic β cell function and glycemic control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsGlaxoSmithKline

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 19, 2005
Enrollment StartSep 1, 2005
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.9 years ago

Interventions

Avandametdrug

Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.

Avandia and Amaryldrug

Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.

Metformindrug

Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily